The Pathak lab is within the Division of Cancer Imaging Research in the Department of Radiology and Radiological Science. We develop novel imaging methods, computational models and visualization tools to ‘make visible’ critical aspects of cancer, stroke and neurobiology. Our research broadly encompasses the following areas: Functional and Molecular Imaging; Clinical Biomarker Development; Image-based Systems Biology and Visualization and Computational Tools. We are dedicated to mentoring the next generation of imagers, biomedical engineers and visualizers. Additional information can be found at www.pathaklab.org or by emailing Dr. Pathak.

Chronic rhinosinusitis (CRS) is a leading cause of morbidity globally and is the single most common self-reported chronic health condition and accounts for billions of dollars in health care costs and lost work days annually. Exposure to air pollutants is thought to be a critical modifier of CRS susceptibility. Despite marked reductions in air pollution levels in the United States, the fine particulate component of air pollution (PM2.5) and ultrafine pollutants secondary to traffic continue to remain a recalcitrant issue globally and in the United States. The Ramanathan Lab focuses on studying the role of air pollution (PM2.5) in CRS. In collaboration with scientists at the Bloomberg School of Public Health, we have utilized a state of the art air pollution exposure system to develop a novel mouse model of air pollution induced rhinosinusitis that mimics many of the features of CRS in humans. Our lab uses transgenic mouse models and novel immunologic/genomic techniques to study the mechanisms by which PM2.5 causes eosinophilic inflammation and sinonasal epithelial barrier dysfunction. We are also interested in the role of the antioxidant transcription factor, Nrf2, which has shown to stabilize the epithelial barrier and reduce eosinophilia in PM induced rhinosinusitis as a potential therapeutic target.

The RISE Lab’s research focuses on developing and evaluating cellular/molecular imaging biosensors and drug/nanoparticle delivery systems for improved therapeutic indices in precision medicine.

The Sfanos Lab studies the cellular and molecular pathology of prostate disease at the Johns Hopkins University School of Medicine. We are specifically interested in agents that may lead to chronic inflammation in the prostate, such as bacterial infections and prostatic concretions called corpora amylacea. Our ongoing studies are aimed at understanding the influence of prostate infections and inflammation on prostate disease including prostate cancer and benign prostatic hyperplasia (BPH). The laboratory also focuses on the influence of the microbiome on prostate disease development, progression, and/or resistance to therapy.

Five to 35 percent of spine fusionprocedures fail, even when using the gold standard treatment of grafting bone from the patient's own iliac crest. Fusion failure, otherwise known as pseudoarthrosis, is a major cause of failed back surgery syndrome (FBSS) and results in significant pain and disability, increasing the need for additional procedures and driving up health care costs. The ultimate goal of the Spinal Fusion Laboratory is to eliminate pseudoarthrosis by using animal models to study various strategies for improving spinal fusion outcomes, including delivery of various growth factors and biological agents; stem cell therapies and tissue engineering approaches.

The nervous system has extremely complex RNA processing regulation. Dysfunction of RNA metabolism has emerged to play crucial roles in multiple neurological diseases. Mutations and pathologies of several RNA-binding proteins are found to be associated with neurodegeneration in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). An alternative RNA-mediated toxicity arises from microsatellite repeat instability in the human genome. The expanded repeat-containing RNAs could potentially induce neuron toxicity by disrupting protein and RNA homeostasis through various mechanisms. The Sun Lab is interested in deciphering the RNA processing pathways altered by the ALS-causative mutants to uncover the mechanisms of toxicity and molecular basis of cell type-selective vulnerability. Another major focus of the group is to identify small molecule and genetic inhibitors of neuron toxic factors using various high-throughput screening platforms. Finally, we are also highly interested in developing novel CRISPR technique-based therapeutic strategies. We seek to translate the mechanistic findings at molecular level to therapeutic target development to advance treatment options against neurodegenerative diseases.

The Swenor Research Group focuses on examining the interrelationship between vision loss and aging. This includes determining the effects of visual impairment and eye disease on physical and cognitive functioning in older adults, and identifying interventions that could enhance the health of older adults with visual impairment and eye disease.

The Vascularized Composite Allotransplantation (VCA) Research Lab is leading research aimed at warding against rejection and reducing the number of medications patients have to take for the rest of their lives. They’re testing a protocol that involves treating the patient with antibodies on the day of transplant, followed by a donor bone marrow infusion several days later. This protocol would allow patients to be treated with low doses of a single maintenance drug after being transplanted.

Dr. Vernon’s Laboratory at the Department of Genetic Medicine develops and studies cellular models of mitochondrial disorders to understand their biological basis and to find new targets for therapeutic intervention.

The Theresa Shapiro Laboratory studies antiparasitic chemotherapy. On a molecular basis, we are interested in understanding the mechanism of action for existing antiparasitic agents, and in identifying vulnerable metabolic targets for much-needed, new, antiparasitic chemotherapy. Clinically, our studies are directed toward an evaluation, in humans, of the efficacy, pharmacokinetics, metabolism and safety of experimental antiparasitic drugs.